|
US5652258A
(en)
*
|
1995-05-30 |
1997-07-29 |
Gliatech, Inc. |
2-(4-imidazoyl) cyclopropyl derivatives
|
|
US6008240A
(en)
*
|
1997-12-15 |
1999-12-28 |
Gliatech, Inc. |
2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
|
|
WO2000042023A1
(en)
|
1999-01-18 |
2000-07-20 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US7265115B2
(en)
|
1999-01-29 |
2007-09-04 |
Abbott Laboratories |
Diazabicyclic CNS active agents
|
|
US6908926B1
(en)
|
1999-04-16 |
2005-06-21 |
Novo Nordisk A/S |
Substituted imidazoles, their preparation and use
|
|
US6114350A
(en)
*
|
1999-04-19 |
2000-09-05 |
Nen Life Science Products, Inc. |
Cyanine dyes and synthesis methods thereof
|
|
US6610721B2
(en)
|
2000-03-17 |
2003-08-26 |
Novo Nordisk A/S |
Imidazo heterocyclic compounds
|
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
|
EP1313470A4
(en)
|
2000-08-17 |
2005-02-16 |
Gliatech Inc |
NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
|
|
EP1320364A1
(en)
*
|
2000-08-21 |
2003-06-25 |
Gliatech, Inc. |
The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity
|
|
WO2002067938A2
(en)
*
|
2000-10-30 |
2002-09-06 |
Schering Corporation |
Treating or reducing the risk of cardiovascular disease
|
|
AU2003248584A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Warner-Lambert Company Llc |
Method of treating osteoarthritis
|
|
EP1720847A1
(en)
*
|
2004-02-02 |
2006-11-15 |
Pfizer Products Incorporated |
Histamine-3 receptor modulators
|
|
US7902191B2
(en)
|
2004-02-25 |
2011-03-08 |
Eli Lilly And Company |
Histamine H3 receptor antagonists, preparation and therapeutic uses
|
|
CA2561628C
(en)
|
2004-04-01 |
2012-05-08 |
Eli Lilly And Company |
Histamine h3 receptor agents, preparation and therapeutic uses
|
|
CN1956952B
(zh)
*
|
2004-06-02 |
2013-12-11 |
伊莱利利公司 |
组胺h3受体药剂、制备和治疗学用途
|
|
EP1784400B1
(en)
|
2004-08-23 |
2015-01-14 |
Eli Lilly And Company |
Histamine h3 receptor agents, preparation and therapeutic uses
|
|
WO2006044228A1
(en)
|
2004-10-18 |
2006-04-27 |
Eli Lilly And Company |
Histamine h3 receptor inhibitors, preparation and therapeutic uses
|
|
DE602006010833D1
(de)
*
|
2005-03-17 |
2010-01-14 |
Lilly Co Eli |
Pyrrolidinderivate als histamin-h3-rezeptorantagonisten
|
|
EP1707203A1
(en)
|
2005-04-01 |
2006-10-04 |
Bioprojet |
Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
|
|
CN101151244B
(zh)
|
2005-04-01 |
2014-09-03 |
伊莱利利公司 |
组胺h3受体活性剂、制备和治疗用途
|
|
EP1717233A1
(en)
*
|
2005-04-29 |
2006-11-02 |
Bioprojet |
Histamine H3-receptor ligands and their therapeutic application
|
|
EP1717235A3
(en)
|
2005-04-29 |
2007-02-28 |
Bioprojet |
Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
|
|
US20100137391A1
(en)
*
|
2005-09-15 |
2010-06-03 |
Ryo Yoshimoto |
Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder
|
|
EP1942104A1
(en)
*
|
2006-12-20 |
2008-07-09 |
sanofi-aventis |
Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
WO2011035941A1
(en)
|
2009-09-25 |
2011-03-31 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011106574A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
WO2011106106A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
RS55348B1
(sr)
|
2010-04-19 |
2017-03-31 |
Oryzon Gnomics S A |
Inhibitori lizin specifične demetilaze-1 i njihova upotreba
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
DK2598482T3
(en)
|
2010-07-29 |
2018-06-14 |
Oryzon Genomics Sa |
ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
|
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
US9469597B2
(en)
|
2011-10-20 |
2016-10-18 |
Oryzon Genomics S.A. |
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
AU2012324803B9
(en)
|
2011-10-20 |
2017-08-24 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
|
WO2013151982A1
(en)
|
2012-04-03 |
2013-10-10 |
Arena Pharmaceuticals, Inc. |
Methods and compounds useful in treating pruritus, and methods for identifying such compounds
|